|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EP3409278B8
(en)
|
2011-07-21 |
2020-11-04 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclic protein kinase inhibitors
|
|
CA2925421C
(en)
|
2013-09-24 |
2023-08-29 |
Medicenna Therapeutics, Inc. |
Interleukin-2 fusion proteins and uses thereof
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
AU2016219772A1
(en)
|
2015-02-22 |
2017-09-21 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD137
|
|
JP2018510151A
(ja)
*
|
2015-03-06 |
2018-04-12 |
ソレント・セラピューティクス・インコーポレイテッド |
Ｔｉｍ３に結合する抗体医薬
|
|
EP4086264B1
(en)
|
2015-05-18 |
2023-10-25 |
Sumitomo Pharma Oncology, Inc. |
Alvocidib prodrugs having increased bioavailability
|
|
MY199098A
(en)
|
2016-04-12 |
2023-10-12 |
Symphogen As |
Anti-tim-3 antibodies and compositions
|
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
TWI895621B
(zh)
|
2016-05-27 |
2025-09-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
US11472856B2
(en)
|
2016-06-13 |
2022-10-18 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
EP4512829A3
(en)
|
2016-07-14 |
2025-06-11 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
SG11201901077RA
(en)
|
2016-08-17 |
2019-03-28 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
TWI665216B
(zh)
*
|
2016-12-29 |
2019-07-11 |
財團法人生物技術開發中心 |
抗人類tim-3抗體及其使用方法
|
|
US11345753B2
(en)
|
2017-02-27 |
2022-05-31 |
Jiangsu Hengrui Medicine Co., Ltd. |
TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof
|
|
JP2020513009A
(ja)
|
2017-04-05 |
2020-04-30 |
シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ |
Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
BR112019025035A2
(pt)
|
2017-06-01 |
2020-06-30 |
Compugen Ltd. |
método para tratar câncer
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
US11542312B2
(en)
|
2017-06-19 |
2023-01-03 |
Medicenna Therapeutics, Inc. |
IL-2 superagonists in combination with anti-PD-1 antibodies
|
|
KR20200021087A
(ko)
|
2017-06-22 |
2020-02-27 |
노파르티스 아게 |
Cd73에 대한 항체 분자 및 이의 용도
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
WO2018234879A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
JP2020525483A
(ja)
|
2017-06-27 |
2020-08-27 |
ノバルティス アーゲー |
抗ｔｉｍ−３抗体のための投与レジメンおよびその使用
|
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
|
US11214615B2
(en)
|
2017-07-28 |
2022-01-04 |
Phanes Therapeutics, Inc. |
Anti-TIM-3 antibodies and uses thereof
|
|
KR20200044899A
(ko)
|
2017-08-28 |
2020-04-29 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료 및 진단을 위한 tim-3 길항제
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
RU2020119578A
(ru)
|
2017-11-16 |
2021-12-17 |
Новартис Аг |
Комбинированные терапии
|
|
SG11202005005YA
(en)
|
2017-11-30 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
EP3737408A1
(en)
|
2018-01-08 |
2020-11-18 |
Novartis AG |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
EP3740506A1
(en)
|
2018-01-16 |
2020-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|
|
AU2019215031B2
(en)
|
2018-01-31 |
2025-10-09 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
CN110144011B
(zh)
*
|
2018-02-14 |
2020-06-23 |
上海洛启生物医药技术有限公司 |
针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体
|
|
PE20210665A1
(es)
|
2018-03-23 |
2021-03-31 |
Bristol Myers Squibb Co |
Anticuerpos contra mica y/o micb y sus usos
|
|
US11807683B2
(en)
|
2018-04-12 |
2023-11-07 |
Nanjing Leads Biolabs Co., Ltd. |
Antibody binding TIM-3 and use thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
JP7398396B2
(ja)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Ｂｃｍａに対する結合分子及びその使用
|
|
PL3820573T3
(pl)
|
2018-07-10 |
2024-02-19 |
Novartis Ag |
Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
CN112512582B
(zh)
|
2018-08-20 |
2024-04-16 |
江苏恒瑞医药股份有限公司 |
Tim-3抗体在制备治疗肿瘤的药物中的用途
|
|
AU2019330702A1
(en)
|
2018-08-28 |
2021-04-08 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-TIM3 antibody pharmaceutical composition and use thereof
|
|
AU2019349651B2
(en)
*
|
2018-09-27 |
2023-12-07 |
Celgene Corporation |
SIRP alpha binding proteins and methods of use thereof
|
|
US11591390B2
(en)
|
2018-09-27 |
2023-02-28 |
Celgene Corporation |
SIRP-α binding proteins and methods of use thereof
|
|
CA3119807A1
(en)
|
2018-12-04 |
2020-06-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
WO2020119719A1
(en)
*
|
2018-12-12 |
2020-06-18 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Anti-tim-3 antibodies and uses thereof
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
WO2020128894A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
US20220025036A1
(en)
|
2018-12-21 |
2022-01-27 |
Novartis Ag |
Use of il-1beta binding antibodies
|
|
IL282838B2
(en)
|
2018-12-21 |
2025-05-01 |
Valerio Therapeutics |
Conjugated nucleic acid molecules and their uses
|
|
CN113227137A
(zh)
|
2018-12-21 |
2021-08-06 |
诺华股份有限公司 |
IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
|
|
KR20210108422A
(ko)
|
2018-12-21 |
2021-09-02 |
노파르티스 아게 |
IL-1β 결합 항체의 용도
|
|
WO2020146902A2
(en)
*
|
2019-01-11 |
2020-07-16 |
Minerva Biotechnologies Corporation |
Anti-variable muc1* antibodies and uses thereof
|
|
CA3127502A1
(en)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2020206169A1
(en)
|
2019-04-02 |
2020-10-08 |
Kupper Thomas S |
Methods for identifying progression of a primary melanoma
|
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
|
EP3977132A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
CN114174538A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
适合于免疫肿瘤学疗法的多肿瘤基因特征
|
|
WO2021003417A1
(en)
|
2019-07-03 |
2021-01-07 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
|
|
WO2021053490A1
(en)
|
2019-09-16 |
2021-03-25 |
Novartis Ag |
Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
|
MX2022004766A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Terapias combinadas con venetoclax e inhibidores de tim-3.
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
|
KR102536302B1
(ko)
*
|
2020-02-25 |
2023-05-26 |
국립암센터 |
Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
CN113214396B
(zh)
*
|
2020-07-31 |
2022-04-19 |
北京市神经外科研究所 |
抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3190660A1
(en)
|
2020-08-31 |
2022-03-03 |
George C. Lee |
Cell localization signature and immunotherapy
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
SMT202500208T1
(it)
|
2020-12-28 |
2025-07-22 |
Bristol Myers Squibb Co |
Composizioni anticorpali e metodi per il loro uso
|
|
CA3196999A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Methods of treating tumors
|
|
EP4083065A1
(en)
|
2021-01-28 |
2022-11-02 |
NantBio, Inc. |
Anti-tim3 monoclonal antibodies and chimeric antigen receptors
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3213079A1
(en)
|
2021-04-13 |
2022-10-20 |
Kristin Lynne ANDREWS |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
US20240391997A1
(en)
*
|
2021-07-16 |
2024-11-28 |
Brightpath Biotherapeutics Co., Ltd. |
Anti-tim-3 antigen antibody or antibody derivative, and use thereof
|
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
|
US20240294926A1
(en)
|
2021-12-16 |
2024-09-05 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
|
WO2023174278A1
(zh)
*
|
2022-03-14 |
2023-09-21 |
正大天晴药业集团南京顺欣制药有限公司 |
抗tim-3抗体与去甲基化药物的药物组合
|
|
KR20240159621A
(ko)
|
2022-03-18 |
2024-11-05 |
브리스톨-마이어스 스큅 컴퍼니 |
폴리펩티드를 단리하는 방법
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
US20240261406A1
(en)
|
2023-02-02 |
2024-08-08 |
Minerva Biotechnologies Corporation |
Chimeric antigen receptor compositions and methods for treating muc1* diseases
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|